PurePEG

Executive Summary

PurePEG is a San Diego-based biotechnology company founded in 2015 that specializes in advanced PEGylation technologies and custom polyethylene glycol (PEG) reagents. The company's products enhance the pharmacokinetics, stability, and efficacy of therapeutic proteins, peptides, and biologics, addressing a critical need in drug delivery. With the global PEGylation market projected to grow significantly, driven by increasing biologics development and demand for longer-acting therapeutics, PurePEG is well-positioned to capture market share. The company offers a range of high-purity PEG reagents and custom conjugation services, serving biopharmaceutical clients from early-stage research to commercial manufacturing. Despite being privately held and not disclosing funding or valuation, PurePEG's presence in the biotech hub of San Diego and its focus on a key enabling technology suggest steady growth potential.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation High-Purity PEG Reagents70% success
• Q1 2027Strategic Partnership with Top-20 Pharmaceutical Company60% success
• Q2 2027Series B Funding Round for Manufacturing Scale-Up75% success